Document Detail

Glutamatergic approaches in major depressive disorder: focus on ketamine, memantine and riluzole.
MedLine Citation:
PMID:  22844658     Owner:  NLM     Status:  In-Data-Review    
The role of glutamate in modulating various mood states is being increasingly recognized and researched. Existing antidepressants have been shown to exert effects on various glutamatergic mechanisms, even if such agents are traditionally classified as working via other mechanisms, such as selective serotonin reuptake inhibitors. The NMDA receptor antagonist ketamine has been investigated in various mood disorders, especially major depressive disorder (MDD). It was found to produce a rapid, robust and persistent antidepressant effect. Although it can produce cognitive, dissociative and perceptual disturbances, these tend to be transient and do not outlast the antidepressant effect. Trials with memantine and riluzole, agents with actions broadly similar to and different from ketamine on the glutamatergic system, are also reviewed in MDD and prospects for future research in the area are discussed. Although preclinical studies are discussed, the main focus of the review is on clinical outcomes.
R T Owen
Related Documents :
23026378 - Comt and bdnf interacted in bipolar ii disorder not comorbid with anxiety disorder.
24936838 - Psychiatric disorders and their association with burn-related factors in children with ...
24717138 - Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety diso...
23352318 - Suicide attempts and psychological risk factors in patients with bipolar and unipolar a...
21887198 - Dandy-walker variant associated with bipolar affective disorder.
25481508 - Reduced cortical surface area in adolescents with conduct disorder.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Drugs of today (Barcelona, Spain : 1998)     Volume:  48     ISSN:  1699-3993     ISO Abbreviation:  Drugs Today     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101160518     Medline TA:  Drugs Today (Barc)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  469-78     Citation Subset:  IM    
Copyright Information:
Copyright 2012 Prous Science, S.A.U. or its licensors. All rights reserved.
Crewe, Cheshire, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vismodegib in basal cell carcinoma.
Next Document:  Heart failure biomarkers: focus on interleukin-1 receptor-like 1-based blood tests.